Download Sample
Add to CartGlobal Liver Cancer Diagnostic Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Test Type;
AFP Tests, LFTs, Biopsy and OthersBy Cancer Stages;
Stage 0, Stage I , Stage II, Stage III, and Stage IVBy Cancer Type;
Primary Liver Cancer and Secondary Liver CancerBy Product;
Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other ConsumablesBy Screening Type;
Laboratory Tests and Biomarker Tests - Oncofetal & Glycoprotein Antigens, Enzymes & Isoenzymes, Growth Factors & Receptors, Molecular Markers, Pathological Biomarkers & Blood Tests, Imaging, Endoscopy, Biopsy and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Liver Cancer Diagnostic Market Overview
Liver Cancer Diagnostic Market (USD Million)
Liver Cancer Diagnostic Market was valued at USD 3,894.52 million in the year 2024. The size of this market is expected to increase to USD 6,172.38 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.8%.
Global Liver Cancer Diagnostic Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 6.8 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 6.8 % |
| Market Size (2024) | USD 3,894.52 Million |
| Market Size (2031) | USD 6,172.38 Million |
| Market Concentration | Medium |
| Report Pages | 376 |
Major Players
- Qiagen N.V.
- Hologic, Inc.
- Bio-Rad Laboratories, Inc.
- GE Healthcare
- Illumina, Inc.
- Sysmex Corporation
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Liver Cancer Diagnostic Market
Fragmented - Highly competitive market without dominant players
The Liver Cancer Diagnostic Market is expanding steadily, propelled by the increasing incidence of liver malignancies and the urgent need for early detection. Liver cancer remains one of the most lethal cancers, primarily due to delayed diagnosis. In fact, nearly 70% of cases are identified in advanced stages, which drastically reduces treatment effectiveness. This pressing health challenge is fueling demand for diagnostic tools capable of identifying the disease at earlier, more treatable stages.
Shift Toward Non-Invasive Testing Solutions
There is a marked transition in clinical preferences toward non-invasive diagnostic techniques that offer greater comfort and safety for patients. Methods such as imaging diagnostics, biomarker detection, and liquid biopsies are now more widely utilized due to their accuracy and lower procedural risk. Currently, non-invasive approaches account for approximately 60% of all liver cancer diagnostic procedures, emphasizing the growing appeal of patient-centric innovations.
Innovation Accelerates Diagnostic Capabilities
The market is being reshaped by rapid technological progress, particularly in imaging, molecular diagnostics, and AI-powered analysis. These advancements are enabling faster, more reliable detection of cancerous lesions. More than 50% of oncology-related diagnostic investments are now focused on digital and automated platforms, reinforcing the industry's shift toward intelligent, high-precision diagnostics.
Rising Adoption of Precision Medicine
Diagnostic techniques that support personalized treatment plans are gaining traction, particularly those involving genetic profiling and companion diagnostics. Such tools are increasingly integrated into liver cancer management, with around 45% of diagnostic protocols now including molecular analysis to guide individualized therapies. This trend is enhancing treatment accuracy and overall patient outcomes.
Policy Support and Awareness Programs Fuel Market Growth
Supportive healthcare initiatives and awareness campaigns are further catalyzing the adoption of liver cancer diagnostics. Structured diagnostic programs are becoming more common, particularly within high-risk population management. Today, more than 40% of chronic liver care frameworks incorporate dedicated diagnostic pathways, underscoring the critical role of early detection in improving survival rates and reducing disease burden.
Liver Cancer Diagnostic Market Recent Developments
-
In December 2022, FUJIFILM Holdings America Corporation entered into a definitive agreement to acquire the digital pathology division of Inspirata, Inc. as part of its strategy to strengthen its enterprise imaging portfolio. This acquisition supports FUJIFILM's broader mission to enhance diagnostic workflows by integrating pathology images and data directly into electronic health record (EHR) systems. The move is expected to significantly improve the efficiency of care coordination, particularly in oncology, by enabling seamless access to comprehensive diagnostic data within a unified digital environment.
-
In January 2022, Merck's immunotherapy drug Keytruda received conditional approval for the treatment of liver cancer, following positive outcomes from its second confirmatory clinical trial. The study demonstrated that in patients with hepatocellular carcinoma, particularly those of Asian descent, Keytruda was able to reduce the risk of death by 21% compared to those receiving a placebo. This milestone reinforces the growing clinical value of immunotherapy in advancing treatment outcomes for liver cancer patients.
Liver Cancer Diagnostic Market Segment Analysis
In this report, the Liver Cancer Diagnostic Market has been segmented by Test Type, Cancer Stages, Cancer Type, Product, Screening Type and Geography.
Liver Cancer Diagnostic Market, Segmentation by Test Type
The Liver Cancer Diagnostic Market has been segmented by Test Type into AFP Tests, LFTs, Biopsy and Others.
AFP Tests
AFP tests (Alpha-fetoprotein tests) serve as a primary tool in the early detection of liver cancer, especially hepatocellular carcinoma (HCC). These tests identify elevated AFP protein levels in the blood, which can be an indicator of liver malignancies. Representing approximately 30% of the liver cancer diagnostics market, AFP tests are preferred due to their non-invasive nature and affordability. Their widespread adoption in regions with high liver cancer incidence makes them a cornerstone in initial diagnostic workflows.
Liver Function Tests (LFTs)
LFTs play a critical role in assessing overall liver function by measuring levels of enzymes and proteins in the bloodstream. While not exclusively diagnostic of liver cancer, they are pivotal in tracking liver abnormalities and guiding further diagnostic procedures. Making up nearly 25% of the market, LFTs are a standard practice in hospitals and diagnostic labs due to their reliability in evaluating liver damage or disease progression, especially in at-risk patients.
Biopsy
A liver biopsy provides a definitive diagnosis by examining a sample of liver tissue under a microscope. Although it contributes to about 20% of the liver cancer diagnostics market, it remains the most accurate method. The procedure is generally reserved for cases where other tests like imaging or blood analyses yield uncertain results. Despite its diagnostic accuracy, the invasive nature, higher cost, and potential complications limit its frequent usage in comparison to other methods.
Others
The "Others" category encompasses advanced diagnostic tools such as imaging techniques (CT scans, MRIs), molecular diagnostics, and liquid biopsies. These methods collectively account for the remaining 25% of the market. The rise in technological innovation and the demand for precise, early detection tools have accelerated the adoption of these solutions. As healthcare systems globally invest in modernization, the role of these next-generation diagnostic tools is expected to expand significantly.
Liver Cancer Diagnostic Market, Segmentation by Cancer Stages
The Liver Cancer Diagnostic Market has been segmented by Cancer Stages into Stage 0, Stage I , Stage II, Stage III, and Stage IV.
Stage 0
Stage 0 liver cancer is the earliest stage, marked by a single, small tumor with no signs of vascular invasion or metastasis. Representing about 10% of diagnosed liver cancer cases, it is often discovered incidentally during routine medical checks. At this early point, treatment options such as surgical resection, radiofrequency ablation, or liver transplantation offer high success rates. Early intervention in Stage 0 significantly boosts long-term survival and recovery prospects.
Stage I and Stage II
Stage I liver cancer involves a single tumor without vascular involvement, while Stage II may present with minor blood vessel invasion or multiple small tumors within the same liver lobe. Combined, these two stages account for approximately 35% of liver cancer diagnoses. High-resolution imaging, AFP blood tests, and MRI scans are commonly used to confirm the extent of the disease. These stages are still considered operable, and patients often respond well to curative treatments, including surgery, targeted therapy, or radioembolization.
Stage III
Stage III liver cancer signifies a more advanced form, with tumors invading nearby major blood vessels or spreading to nearby organs and lymph nodes. Approximately 30% of cases are diagnosed at this stage. A multi-modal diagnostic approach is crucial here, combining CT scans, biopsies, and PET imaging to understand the disease's full extent. Although more complex, treatment options like combination therapies and clinical trials can offer life-extending benefits when properly administered.
Stage IV
Stage IV liver cancer is the most advanced stage, where cancer has spread to distant parts of the body, such as the lungs, bones, or brain. This stage makes up about 25% of diagnosed cases. Diagnostic efforts at this stage focus on comprehensive metastatic mapping through full-body imaging and blood markers. While curative treatment is rarely possible, patients benefit from palliative care, chemotherapy, and immunotherapy aimed at improving quality of life and managing symptoms.
Liver Cancer Diagnostic Market, Segmentation by CancerType
The Liver Cancer Diagnostic Market has been segmented by Cancer Type into Primary Liver Cancer and Secondary Liver Cancer.
Primary Liver Cancer
Primary liver cancer begins within the liver itself, with hepatocellular carcinoma (HCC) being the most dominant subtype. Representing approximately 70% of the global liver cancer diagnostic market, it is often linked to chronic liver conditions like hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD). Diagnostics for primary liver cancer typically include AFP blood tests, ultrasound imaging, MRI scans, and liver biopsies. The high prevalence of HCC, particularly in Asia and Africa, makes this segment the largest contributor to diagnostic demand, highlighting the need for regular screening in high-risk populations.
Secondary Liver Cancer
Secondary liver cancer, or metastatic liver cancer, originates in other organs such as the colon, breast, pancreas, or lungs, and subsequently spreads to the liver. This segment constitutes about 30% of the diagnostic market. Due to the liver’s rich blood supply, it frequently becomes a site for metastasis. Accurate diagnosis involves comprehensive imaging techniques, tumor marker evaluations, and histopathological tests to identify both the liver involvement and the origin of the primary cancer. While less dominant than primary liver cancer in origin, it remains a critical focus of diagnostic strategies due to its complex presentation and implications for treatment planning.
Liver Cancer Diagnostic Market, Segmentation by Product
The Liver Cancer Diagnostic Market has been segmented by Product into Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables.
Platform-Based Products
Platform-based diagnostic products are becoming essential in enhancing efficiency and accuracy in liver cancer detection. These include AI-powered diagnostic platforms, image analysis software, and data integration systems that support clinicians in making informed decisions. Accounting for around 28% of the global market, their growth is driven by increasing digitalization and the need for automated workflows. The integration of these platforms with hospital systems improves diagnostic turnaround time and fosters personalized medicine approaches.
Instrument Based Products
Instrument-based products form the backbone of liver cancer diagnostics, including devices such as MRI and CT scanners, automated blood analyzers, and biopsy instruments. With the largest market share of approximately 40%, these tools are critical for accurate imaging, tumor localization, and biological sampling. The demand for such instruments remains high in both public hospitals and private diagnostic centers, as they enable in-depth assessments of liver abnormalities.
Kits and Reagents
Diagnostic kits and reagents play a pivotal role in biochemical and molecular testing, including AFP tests, liver function tests, and genetic markers for liver cancer. Comprising around 22% of the market, these consumables are used frequently in labs for both screening and follow-up diagnostics. Their cost-effectiveness, combined with growing awareness and accessibility of early detection tools, is fueling steady market demand, especially in routine laboratory workflows.
Other Consumables
Other consumables, such as sample vials, glass slides, buffer solutions, and staining agents, are integral to the diagnostic workflow. Although this segment holds a smaller share at 10%, these products are indispensable in supporting the use of primary diagnostic tools. Their rising consumption in high-volume diagnostic labs and emerging healthcare facilities contributes to a consistent upward trend in demand.
Liver Cancer Diagnostic Market, Segmentation by Screening Type
The Liver Cancer Diagnostic Market has been segmented by Screening Type into Laboratory Tests, Biomarker Tests, Imaging, Endoscopy, Biopsy and Others.
Laboratory and Biomarker Tests
Laboratory diagnostics and biomarker screening are foundational in detecting liver cancer at an early stage. This category includes tests targeting oncofetal antigens, glycoprotein antigens, enzymes, growth factor receptors, molecular markers, and pathological blood biomarkers. Collectively accounting for about 42% of the market, these tests offer minimally invasive, quick, and cost-effective solutions. Their growing adoption, particularly in high-risk groups, is driven by their ability to detect cancer before symptoms arise, making them vital to early intervention strategies.
Imaging Techniques
Imaging-based screening is a cornerstone of liver cancer diagnostics. Tools such as ultrasound, MRI, and CT scans are used extensively to identify liver tumors, determine their characteristics, and guide clinical decisions. Representing approximately 30% of the screening market, these modalities provide critical visual insights, especially in asymptomatic cases. Their value lies in their ability to deliver precise and reproducible results that inform both diagnosis and treatment planning.
Endoscopy and Biopsy
Endoscopic procedures and biopsies serve as confirmatory methods in liver cancer diagnostics. Although comprising about 18% of the market, they are essential when initial tests yield inconclusive results. A biopsy remains the definitive test for diagnosing liver cancer, offering detailed information about tumor histology and grade. Despite being invasive, these techniques are indispensable for obtaining a comprehensive clinical picture in complex cases.
Other Screening Methods
Other screening approaches, including liquid biopsy, elastography, and NGS-based methods, are emerging rapidly in the diagnostics landscape. These innovative techniques account for the remaining 10% of the screening segment. Their strengths lie in offering non-invasive, highly sensitive, and precise molecular insights, paving the way for personalized treatment pathways and future growth in predictive diagnostics.
Liver Cancer Diagnostic Market, Segmentation by Geography
In this report, the Liver Cancer Diagnostic Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Liver Cancer Diagnostic Market Share (%), by Geographical Region, 2024
North America
North America dominates the liver cancer diagnostics market, contributing around 35% of the total revenue. This leadership is driven by a combination of cutting-edge diagnostic technology, extensive screening programs, and a strong healthcare ecosystem. The region benefits from high awareness of liver cancer risks and the early adoption of AI-driven imaging and molecular testing platforms, especially in the United States and Canada.
Europe
Europe holds a market share of approximately 25%, supported by advanced healthcare systems and a strong focus on early cancer detection. Major economies such as Germany, France, and the UK invest significantly in public health initiatives aimed at improving liver cancer outcomes. The presence of established diagnostic players and continuous funding in cancer research contribute to the region’s consistent performance.
Asia Pacific
Asia Pacific is witnessing rapid expansion, currently representing about 28% of the global market. A high burden of hepatitis-related liver cancers, coupled with increased efforts in public health education and screening accessibility, is driving market growth. Countries such as China, India, and Japan are leading the regional surge due to rising healthcare expenditure and growing acceptance of advanced diagnostics.
Middle East and Africa, and Latin America
The Middle East and Africa and Latin America jointly contribute to the remaining 12% of the market. While still in developmental phases, these regions are showing promising signs of growth through international collaborations, infrastructure enhancements, and increased awareness of liver cancer diagnostics. Ongoing government efforts and support from global health organizations are expected to further strengthen their role in the coming years.
Liver Cancer Diagnostic Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Liver Cancer Diagnostic Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Incidence of Liver Cancer
- Advancements in Diagnostic Technologies
- Rising Awareness and Screening Programs
- Emergence of Novel Biomarkers
-
Adoption of Artificial Intelligence (AI) in Diagnostic Imaging - The increasing integration of Artificial Intelligence (AI) in diagnostic imaging is playing a pivotal role in driving the liver cancer diagnostic market. AI algorithms are transforming how liver cancer is detected by enhancing image interpretation, enabling automated identification of subtle tissue anomalies, and significantly reducing diagnostic variability. These technologies improve early detection capabilities by analyzing complex imaging data from CT, MRI, and ultrasound scans with exceptional precision and speed, supporting faster and more accurate diagnosis than traditional methods.
By streamlining diagnostic workflows, AI systems also help reduce the burden on radiologists, allowing for quicker decision-making and better patient triage. This is especially crucial in liver cancer, where early-stage detection greatly influences prognosis and treatment success. AI-enabled platforms not only flag potential malignancies but also assist in tumor characterization and risk stratification, ultimately leading to more personalized and timely interventions. As AI adoption becomes more widespread in clinical practice, its impact on improving liver cancer diagnosis is expected to grow substantially.
Restraints
- Limited Access to Screening Programs
- High Cost of Diagnostic Procedures
- Challenges in Early Detection
- Lack of Healthcare Infrastructure in Developing Regions
-
Regulatory Hurdles and Reimbursement Issues - Regulatory barriers and reimbursement limitations are major factors constraining the expansion of the liver cancer diagnostic market. The development and commercialization of advanced diagnostic tools—such as AI-integrated imaging platforms and biomarker-based assays—must undergo rigorous regulatory evaluations to ensure clinical reliability and safety. These lengthy and complex approval processes increase time to market and escalate development costs. Smaller firms, in particular, may struggle with the resource demands of regulatory compliance, which can hinder innovation and slow down the introduction of new diagnostic technologies.
Simultaneously, inconsistent or insufficient reimbursement policies create additional challenges for widespread adoption. Many high-precision liver cancer diagnostics are either inadequately reimbursed or excluded from coverage entirely by insurance providers. This financial uncertainty limits their use in routine clinical practice, as healthcare providers are hesitant to adopt costly technologies without guaranteed reimbursement. Patients may also face elevated out-of-pocket expenses, restricting access to early and accurate diagnosis. These combined regulatory and reimbursement issues reduce market penetration and delay the broader implementation of advanced liver cancer diagnostic solutions.
Opportunities
- Expansion of Screening Programs in High-Risk Populations
- Development of Non-Invasive Diagnostic Methods
- Integration of Multi-Disciplinary Approaches to Disease Management
- Emerging Markets and Untapped Potential
-
Research and Development of Personalized Diagnostic Solutions - Expanding efforts in research and development of personalized diagnostic solutions are generating substantial opportunities for the liver cancer diagnostic market. As the understanding of tumor biology deepens, there is a growing shift toward diagnostics that can identify molecular and genetic profiles unique to each patient. These personalized approaches are enabling earlier detection, more accurate disease characterization, and improved treatment planning, thereby supporting the transition toward precision oncology.
Personalized diagnostic tools such as liquid biopsies, gene expression profiling, and biomarker-driven imaging are being actively explored and integrated into clinical workflows. These innovations provide a non-invasive or minimally invasive means of capturing real-time tumor information, which is critical in the management of aggressive liver cancers like hepatocellular carcinoma. As R&D investments increase, the development of companion diagnostics tailored to specific therapies is also accelerating, offering clinicians valuable insights into treatment responsiveness.
Technological advances in bioinformatics, next-generation sequencing (NGS), and artificial intelligence are further enhancing the potential of personalized diagnostics. These tools can analyze complex datasets, detect subtle genetic mutations, and assist in predicting patient outcomes with greater precision. This fusion of data-driven technologies with individualized care models is driving the demand for customized diagnostic platforms across both academic and commercial healthcare sectors.
As healthcare systems worldwide move toward value-based care and outcome-driven treatment, the demand for personalized liver cancer diagnostic solutions is expected to rise significantly. This trend not only promises better clinical outcomes but also positions the market for continued innovation and long-term growth by aligning diagnostics with the evolving paradigm of individualized cancer management.
Liver Cancer Diagnostic Market Competitive Landscape Analysis
Key players in Liver Cancer Diagnostic Market include,
- Abbott Laboratories
- Agilent Technologies Inc.
- Bayer AG
- BD (Becton Dickinson and Company)
- Bio-Rad Laboratories Inc.
- GE Healthcare
- Illumina Inc.
- Merck KGaA
- PerkinElmer Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- Tosoh Corporation
- Sysmex Corporation
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Test Type
- Market Snapshot, By Cancer Stages
- Market Snapshot, By Cancer Types
- Market Snapshot, By Product
- Market Snapshot, By Screening Type
- Market Snapshot, By Region
- Liver Cancer Diagnostic Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Incidence of Liver Cancer
- Advancements in Diagnostic Technologies
- Rising Awareness and Screening Programs
- Emergence of Novel Biomarkers
- Adoption of Artificial Intelligence (AI) in Diagnostic Imaging
- Restraints
- Limited Access to Screening Programs
- High Cost of Diagnostic Procedures
- Challenges in Early Detection
- Lack of Healthcare Infrastructure in Developing Regions
- Regulatory Hurdles and Reimbursement Issues
- Opportunities
- Expansion of Screening Programs in High-Risk Populations
- Development of Non-Invasive Diagnostic Methods
- Integration of Multi-Disciplinary Approaches to Disease Management
- Emerging Markets and Untapped Potential
- Research and Development of Personalized Diagnostic Solutions
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Liver Cancer Diagnostic Market, By Test Type, 2021 - 2031 (USD Million)
- AFP Tests
- LFTs
- Biopsy
- Others
- Liver Cancer Diagnostic Market, By Cancer Stages, 2021 - 2031 (USD Million)
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- Liver Cancer Diagnostic Market, By Cancer Type, 2021 - 2031 (USD Million)
- Primary Liver Cancer
- Secondary Liver Cancer
- Liver Cancer Diagnostic Market, By Product, 2021 - 2031 (USD Million)
- Platform-Based Products
- Instrument Based Products
- Kits and Reagents
- Other Consumables
- Liver Cancer Diagnostic Market, By Screening Type, 2021 - 2031 (USD Million)
- Laboratory Tests
- Biomarker Tests
- Oncofetal & Glycoprotein Antigens
- Enzymes & Isoenzymes
- Growth Factors & Receptors
- Molecular Markers
- Pathological Biomarkers
- Blood Tests
- Imaging
- Endoscopy
- Biopsy
- Others
- Liver Cancer Diagnostic Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia/New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Liver Cancer Diagnostic Market, By Test Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Agilent Technologies Inc.
- Bayer AG
- BD (Becton Dickinson and Company)
- Bio-Rad Laboratories Inc.
- GE Healthcare
- Illumina Inc.
- Merck KGaA
- PerkinElmer Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- Tosoh Corporation
- Sysmex Corporation
- Company Profiles
- Analyst Views
- Future Outlook of the Market